Genmab As Stock Performance
| GMAB Stock | USD 20.80 0.29 1.41% |
Genmab AS has a performance score of 2 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.69, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Genmab AS's returns are expected to increase less than the market. However, during the bear market, the loss of holding Genmab AS is expected to be smaller as well. Genmab AS right now retains a risk of 2.78%. Please check out Genmab AS treynor ratio, skewness, rate of daily change, as well as the relationship between the value at risk and accumulation distribution , to decide if Genmab AS will be following its current trending patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Genmab AS are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Genmab AS is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 1.41 | Five Day Return 2.97 | Year To Date Return (0.95) | Ten Year Return 174.77 | All Time Return 451.72 |
Last Split Factor 5:1 | Last Split Date 2018-05-01 |
1 | Genmab AS Releases Quarterly Earnings Results, Beats Estimates By 0.29 EPS | 02/12/2025 |
2 | EPKINLY Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma | 02/20/2025 |
3 | Is Genmab One of the Best Growth Stocks to Invest In According to Analysts | 02/24/2025 |
4 | Transactions with shares and linked securities in Genmab AS made by managerial employees and their closely associated persons | 02/28/2025 |
5 | Genmab Announces Johnson Johnson Decision Regarding HexaBody-CD38 | 03/10/2025 |
6 | Truist Financial Cuts Genmab AS Price Target to 45.00 | 03/11/2025 |
7 | Genmab AS Sees Large Volume Increase Whats Next | 03/12/2025 |
| Begin Period Cash Flow | 14.9 B |
Genmab |
Genmab AS Relative Risk vs. Return Landscape
If you would invest 2,014 in Genmab AS on December 18, 2024 and sell it today you would earn a total of 66.00 from holding Genmab AS or generate 3.28% return on investment over 90 days. Genmab AS is currently generating 0.0934% in daily expected returns and assumes 2.7797% risk (volatility on return distribution) over the 90 days horizon. In different words, 24% of stocks are less volatile than Genmab, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Genmab AS Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Genmab AS's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genmab AS, and traders can use it to determine the average amount a Genmab AS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0336
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | GMAB | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.78 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.09 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Genmab AS is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genmab AS by adding it to a well-diversified portfolio.
Genmab AS Fundamentals Growth
Genmab Stock prices reflect investors' perceptions of the future prospects and financial health of Genmab AS, and Genmab AS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genmab Stock performance.
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.36 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 10.15 B | ||||
| Shares Outstanding | 635.5 M | ||||
| Price To Earning | 66.53 X | ||||
| Price To Book | 2.44 X | ||||
| Price To Sales | 0.61 X | ||||
| Revenue | 21.53 B | ||||
| Gross Profit | 20.54 B | ||||
| EBITDA | 7.39 B | ||||
| Net Income | 7.84 B | ||||
| Cash And Equivalents | 21.61 B | ||||
| Cash Per Share | 33.05 X | ||||
| Total Debt | 1.03 B | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 13.11 X | ||||
| Book Value Per Share | 577.54 X | ||||
| Cash Flow From Operations | 7.77 B | ||||
| Earnings Per Share | 1.77 X | ||||
| Market Capitalization | 13.07 B | ||||
| Total Asset | 45.81 B | ||||
| Retained Earnings | 23.55 B | ||||
| Working Capital | 22.55 B | ||||
| Current Asset | 12.65 B | ||||
| Current Liabilities | 823.51 M | ||||
About Genmab AS Performance
By analyzing Genmab AS's fundamental ratios, stakeholders can gain valuable insights into Genmab AS's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genmab AS has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genmab AS has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 22.97 | 21.83 | |
| Return On Tangible Assets | 0.25 | 0.27 | |
| Return On Capital Employed | 0.17 | 0.17 | |
| Return On Assets | 0.17 | 0.18 | |
| Return On Equity | 0.21 | 0.22 |
Things to note about Genmab AS performance evaluation
Checking the ongoing alerts about Genmab AS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genmab AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Genmab AS is unlikely to experience financial distress in the next 2 years | |
| Genmab AS has a strong financial position based on the latest SEC filings | |
| Latest headline from thelincolnianonline.com: Genmab AS Sees Large Volume Increase Whats Next |
- Analyzing Genmab AS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genmab AS's stock is overvalued or undervalued compared to its peers.
- Examining Genmab AS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Genmab AS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genmab AS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Genmab AS's stock. These opinions can provide insight into Genmab AS's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |